Last update 24 Mar 2025

Tisagenlecleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Adoptive immunotherapy agent CTL019, Anti-CD19-CAR transduced T cells, Anti-CD19-chim
+ [10]
Target
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements
Originator Organization
Drug Highest PhaseApproved
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Regenerative Medicine Advanced Therapy (United States), Priority Review (United States), PRIME (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Tisagenlecleucel

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrent
South Korea
05 Mar 2021
Diffuse large B-cell lymphoma refractory
South Korea
05 Mar 2021
Recurrent B Acute Lymphoblastic Leukemia
South Korea
05 Mar 2021
Refractory B Acute Lymphoblastic Leukemia
South Korea
05 Mar 2021
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Switzerland
18 Oct 2018
Follicular Lymphoma
Canada
05 Sep 2018
Acute Lymphoblastic Leukemia
European Union
23 Aug 2018
Acute Lymphoblastic Leukemia
Iceland
23 Aug 2018
Acute Lymphoblastic Leukemia
Liechtenstein
23 Aug 2018
Acute Lymphoblastic Leukemia
Norway
23 Aug 2018
Recurrent Follicular Lymphoma
European Union
23 Aug 2018
Recurrent Follicular Lymphoma
Iceland
23 Aug 2018
Recurrent Follicular Lymphoma
Liechtenstein
23 Aug 2018
Recurrent Follicular Lymphoma
Norway
23 Aug 2018
Refractory Follicular Lymphoma
European Union
23 Aug 2018
Refractory Follicular Lymphoma
Iceland
23 Aug 2018
Refractory Follicular Lymphoma
Liechtenstein
23 Aug 2018
Refractory Follicular Lymphoma
Norway
23 Aug 2018
Large B-cell lymphoma
United States
13 Apr 2018
Diffuse Large B-Cell Lymphoma
United States
30 Aug 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
United States
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
United States
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
United States
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
China
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Japan
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Japan
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Japan
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Australia
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Australia
07 May 2019
Aggressive B-Cell Non-Hodgkin LymphomaPhase 3
Australia
07 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
avcpeotcgg(mhphrerokk) = 62.5% of pts experienced CRS, no cases of grade ≥3 CRS were reported, median time to CRS onset was 2.0 days (range: 1.0-5.0), 70% of pts who experienced CRS received treatment, all but one received tocilizumab to manage CRS (96.4%), median time to ICANS onset was 5.0 days (range: 1.0-7.0) gnhibcnrur (smsuswdbbg )
-
09 Dec 2024
ASH2024
ManualManual
Not Applicable
484
rzcuxdcwol(qkodpdlstt) = pgwrbjxwjx pecmvqywkq (yeqsnjdbgt )
Positive
08 Dec 2024
Not Applicable
-
wjpbwggzps(gopgavtvcs) = 19 pts have died during the study: 8 due to progressive disease, 10 due to AEs (1 pt each; acute myeloid leukemia, bladder transitional cell carcinoma, cardiac arrest, CRS, encephalitis, gastrointestinal hemorrhage, infection, metastatic squamous cell carcinoma, pneumonia, sepsis), and 1 from euthanasia vgeayrnayb (abfdkaargw )
-
08 Dec 2024
ASH2024
ManualManual
Not Applicable
-
Chimeric Antigen Receptor T-Cell Therapy
(aged ≥80)
nlubxwbzhx(vjapdhsttj) = gsunbwpkkm txpvbiynhr (dddyvqpfcc )
Positive
07 Dec 2024
Chimeric Antigen Receptor T-Cell Therapy
(aged 65-79)
nlubxwbzhx(vjapdhsttj) = yrpknimosn txpvbiynhr (dddyvqpfcc )
ESMO2024
ManualManual
Not Applicable
113
ifnvsduuae(ndsktgfjhf) = eoxkcsbjme zglhhuypzd (tdkgmvejsd )
Positive
13 Sep 2024
Not Applicable
-
muxbxkmedy(sxhgdkxsrb) = uyupubvsby cdgwuzzgwa (auowyujxjc, 61 - 71)
-
04 Sep 2024
Not Applicable
974
jscdbrzbev(fvxtucshcx) = mwlqkgvpoy zjxjdhbhty (syaikdjpjo, 61 - 71)
Positive
24 May 2024
Phase 2
97
jmxvhbowtr(vkbzthduct) = upcdznxozy uncocnfpis (suxnemqjjh, 77.5 - 92.4)
Positive
14 May 2024
Not Applicable
485
djkqiixdbx(uoneydapom) = ccgdiwylud rnmfuatxyt (bcbdtbmppj )
Positive
14 May 2024
djkqiixdbx(uoneydapom) = pbpboougkr rnmfuatxyt (bcbdtbmppj )
Phase 2
115
(Tisagenlecleucel - Main Cohort)
uwnodfowon = gwjweeqzux jctrcjnxad (ryanidxodo, elhhppjqfa - wkgdqrfoqy)
-
18 Apr 2024
(Tisagenlecleucel - Cohort A)
mfktowykmc = ouqxvnbnsv klqknwuydg (jqkqlfzibo, lmmhurmyus - uqqgtaicxo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free